Abstract
Scientific advances have improved therapies that prevent progression of irreversible joint damage in up to 90% of patients with RA. Early treatment with methotrexate plus glucocorticoids and subsequently with other DMARDs, such as inhibitors of TNF, IL-6, or Janus kinases, improves outcomes and prevents RA-related disability. A treat-to-target strategy aimed at reducing disease activity by at least 50% within 3 months and achieving remission or low disease activity within 6 months, with sequential drug treatment if needed, can prevent RA-related disability.
Keywords
MedicineRheumatoid arthritisMethotrexateDiseaseAdalimumabAntirheumatic AgentsRegimenAntirheumatic drugsInternal medicineIntensive care medicine
MeSH Terms
AlgorithmsAntirheumatic AgentsArthritisRheumatoidBiological ProductsDrug TherapyCombinationGlucocorticoidsHumansMethotrexateRadiographyRisk Factors
Affiliated Institutions
Related Publications
Interleukin-6 Receptor Blockade Selectively Reduces IL-21 Production by CD4 T Cells and IgG4 Autoantibodies in Rheumatoid Arthritis
Interleukin-6 (IL-6) levels are known to be increased in patients with rheumatoid arthritis (RA). Tocilizumab, a monoclonal antibody to the IL-6 receptor (IL-6R), reduces diseas...
Interleukin 6 Is Required for the Development of Collagen-induced Arthritis
Interleukin-6 (IL-6) is overproduced in the joints of patients with rheumatoid arthritis (RA) and, based on its multiple stimulatory effects on cells of the immune system and on...
The Clinical Utility of a Six‐Minute Walk Test in Peripheral Arterial Occlusive Disease Patients
OBJECTIVES: To determine the test‐retest reliability of the distance covered and the steps taken to complete a 6‐minute walk test by peripheral arterial occlusive disease (PAOD)...
Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality
Since the initial description of nonalcoholic steatohepatitis (NASH), several sets of pathologic criteria for its diagnosis have been proposed. However, their interprotocol agre...
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone
Insulin resistance (IR) commonly is associated with nonalcoholic steatohepatitis (NASH). To establish whether IR causes NASH, this study was undertaken to determine if improving...
Publication Info
- Year
- 2018
- Type
- review
- Volume
- 320
- Issue
- 13
- Pages
- 1360-1360
- Citations
- 2063
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
2063
OpenAlex
63
Influential
1840
CrossRef
Cite This
Daniel Aletaha,
Josef S Smolen
(2018).
Diagnosis and Management of Rheumatoid Arthritis.
JAMA
, 320
(13)
, 1360-1360.
https://doi.org/10.1001/jama.2018.13103
Identifiers
- DOI
- 10.1001/jama.2018.13103
- PMID
- 30285183